ABG
AVDL

Ally Bridge Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Ally Bridge Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-430,245
Closed -$6.05M – 30
2024
Q2 		$6.05M Sell
430,245
-116,791
-21% -$1.9M 3.6% 15
2024
Q1 		$9.24M Buy
547,036
+200,000
+58% +$2.98M 5.14% 9
2023
Q4 		$4.9M Buy
+347,036
New +$4.08M 2.92% 15

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Ally Bridge Group's AVDL Position: Q3 2024 in Review

Ally Bridge Group sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 430,245 shares — an estimated $6.05M sold.

Ally Bridge Group first reported a position in AVDL in Q4 2023 and held it in 3 quarters. The position peaked at $9.24M in Q1 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

  • Ally Bridge Group reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Ally Bridge Group sold 430,245 Avadel Pharmaceuticals shares in Q3 2024, an estimated $6.05M.
  • Ally Bridge Group first reported a position in Avadel Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Ally Bridge Group's Avadel Pharmaceuticals position peaked at $9.24M in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on Ally Bridge Group's 13F filing for Q3 2024, filed 14 Nov 2024.